Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines

• Published in: Surgery 1998-12, Vol.124 (6), p.1100-1105
• Main Authors: Chun, Yoon S., Saji, Motoyasu, Zeiger, Martha A.
• Format: Article
• Language: English
• Subjects: DNA-Binding Proteins - genetics; Humans; Nuclear Proteins - genetics; Paired Box Transcription Factors; PAX8 Transcription Factor; Promoter Regions, Genetic - genetics; RNA, Messenger - biosynthesis; Thyroglobulin - genetics; Thyroid Gland; Thyroid Neoplasms - genetics; Thyroid Nuclear Factor 1; Trans-Activators - genetics; Transcription Factors - genetics; Transfection; Tumor Cells, Cultured
• ISSN: 0039-6060; 1532-7361
• DOI: 10.1067/msy.1998.92008

Background: In anticipation of developing gene therapy against thyroid carcinoma we created an expression vector using the thyroglobulin (Tg) gene promoter. The inhibition of both Tg and thyroid-specific transcription factor (TTF-1 and PAX-8) gene expression, however, has been well documented in thyroid carcinomas. We therefore examined the effects of overexpression of TTF-1 and PAX-8 on Tg gene promoter activity in the human thyroid carcinoma cell lines, ARO (anaplastic) and WRO (follicular). Methods: ARO, WRO, and nonthyroid cells were transfected with an expression vector in which β-galactosidase (β-gal) is driven by the Tg gene promoter (β-gal). Tg, TTF-1, and PAX-8 gene expression were also examined by reverse transcriptase–polymerase chain reaction (RT-PCR). Results: ARO and WRO exhibited decreased gene expression of Tg, TTF-1, and PAX-8. Transfection with TG-—gal alone exhibited minimal β-gal expression, whereas cotransfection with TTF-1 and PAX-8 resulted in markedly increased expression. There was no evidence of β-gal expression with or without TTF-1 and PAX-8 in nonthyroid cells. Conclusions: Weak Tg gene promoter activity in ARO and WRO is associated with decreased expression of transcription factors TTF-1 and PAX-8 but can be restored with their overexpression. This model may serve as a template on which to further develop cell-specific gene therapy against thyroid carcinoma. (Surgery 1998;124:1100-5.)